Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Document Type
Journal Article
Publication Date
9-13-2018
Journal
Pharmacological research : the official journal of the Italian Pharmacological Society
Volume
136
Inclusive Pages
140-150
DOI
10.1016/j.phrs.2018.09.007
APA Citation
Conklin, L., Damsker, J., Hoffman, E., Jusko, W., Mavroudis, P., Schwartz, B., Mengle-Gaw, L., Smith, E., Mah, J., Guglieri, M., Nevo, Y., Kuntz, N., McDonald, C., Tulinius, M., Ryan, M., Webster, R., Castro, D., Finkel, R., Smith, A., Morgenroth, L., Arrieta, A., Shimony, M., Jaros, M., Shale, P., McCall, J., Hathout, Y., Nagaraju, K., van den Anker, J., Ward, L., Ahmet, A., Cornish, M., & Clemens, P. (2018). Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.. Pharmacological research : the official journal of the Italian Pharmacological Society, 136 (). http://dx.doi.org/10.1016/j.phrs.2018.09.007
Peer Reviewed
1
